Takeda denies it is in talks to buy Nycomed

13 May 2011

Takeda Pharmaceutical (TSE: 4502), Japan’s largest drugmaker, has emphatically denied that it is in advanced talks to acquire independent Swiss drugmaker Nycomed, as has been strongly rumored over the past few days (The Pharma Letter May 12).

In a statement Takeda says it has and always will comply with the rules governing the publication of any event of material significance to its business and shareholders. “The company would like to make clear that Takeda has not agreed to any such an agreement as suggested by certain newspaper publications. In addition, Takeda has a policy of not commenting on any rumors regarding our business,” it stressed.

“Takeda is constantly seeking and evaluating opportunities to increase shareholder value and enhance our business through strategic investment, however, there is nothing that needs to be announced at this point,” the company says.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK